A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Exclusion Criteria

• •Prior HER-2 targeted therapy for breast cancer
• •Metastatic disease
• •Uncontrolled intercurrent illness including but not limited to, ongoing or active infection requiring parenteral antibiotics or psychiatric illness/social situations that would limit compliance with study requirements.
• •GI tract disease resulting in inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease eg, Crohn's, ulcerative colitis).
• •Current active hepatic or biliary disease (exception of patients with Gilbert's syndrome, asymptomatic gallstones)
• •Renal function as measured by creatinine clearance \<30ml/min (ratio to norm \<0.1)
• •Pregnant
• •Inflammatory breast cancer
• •Active cardiac disease, defined as:
• •* History of uncontrolled or symptomatic angina
• •* History of arrhythmias requiring medications, or clinically significant, with exception of asymptomatic atrial fibrillation requiring anticoagulation
• •* Myocardial infarction \< 6 months from study entry
• •* Uncontrolled or symptomatic congestive heart failure
• •* Any other cardiac condition, which in opinion of treating physician, would make this protocol unreasonably hazardous for the patient
• •History of another primary cancer, with the exception of:
• •* curatively resected nonmelanomatous skin cancer
• •* curatively treated cervical carcinoma in-situ
• •* other primary solid tumor curatively resected,treated with no known active disease present and no treatment administered for the last 3 years.
• •Life expectancy of \< 2 months
• •Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
• •Should not receive immunization with attenuated live vaccines within 1 week of study entry or during study period
• •Severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
• •Uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN
• •Active (acute or chronic) or uncontrolled severe infections
• •Known history of HIV seropositivity
• •Active, bleeding diathesis
• •Patients who have received prior treatment with an mTOR inhibitor (Sirolimus, Temsirolimus, Everolimus).
• •Known hypersensitivity to RAD001 (Everolimus) or other rapamycins (Sirolimus, Temsirolimus) or to its excipients
• •Active Hepatitis B or C infection
• •\> 65 years of age